OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Research in Neurodegenerative Diseases II

Submission Deadline: September 15, 2022 (Open) Submit Now

Guest Editor

Janusz Wieslaw Blaszczyk, PhD, DSc, Professor

Jerzy Kukuczka Academy of Physical Education, Katowice, Poland

Website1 | Website2 | Website3 | E-Mail

Research Interests:Neuroscience; Neurophysiology; Brain aging; Neurodegeneration

About This Topic

Neurodegenerative diseases consist of a group of pathologies related to the progressive dysfunction of neuronal networks in the human brain. Neurodegeneration can be found in the brain at many different levels of neuronal circuitry, ranging from molecular to systemic. Neurodegenerative diseases are incurable and debilitating conditions being the result of massive degeneration and death of brain cells. Depending on the most affected area patients exhibit mental and motor dysfunctions. The incidence of main neurodegenerative pathologies, such as Alzheimer’s and Parkinson's disease, increases with age. To understand and counteract such pathologies, we need to understand their immediate causes at the cellular level.  It seems that many neurodegenerative diseases are caused by genetic mutations. More recently, however, appeared the concept of a vicious cycle in neuronal energy metabolism that may readily explain the involution of the neuronal networks.  The decreasing activity of the strategic brain structures, in turn, results in their metabolic deprivation that disturbed cellular homeostasis and finally initiate preprogrammed death of neuronal cells.  With the increasing understanding of the pathophysiological basis of these disorders, appears now a realistic prospect for developing therapies that may slow, or control the process of neurodegeneration. Importantly therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well.


Neurodegenerative disorders; Brain homeostasis; Aging brain; Genetic background; Energy metabolism; Brain involution